



# Financial Tear Sheet

## Corporate Profile

Blueprint Medicines is developing a new generation of highly selective and potent kinase medicines to improve the lives of patients with genomically defined diseases. The Company's approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing three programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma and systemic mastocytosis, as well as multiple programs in research and preclinical development. For more information, please visit [www.blueprintmedicines.com](http://www.blueprintmedicines.com).

## Primary IR Contact

Kristin Hodous

Blueprint Medicines

**Phone:** 617-714-6674

**E-mail:**

[khodous@blueprintmedicines.com](mailto:khodous@blueprintmedicines.com)

## Stock Information

### BPMC (Common Stock)

Exchange NASDAQ GS (US Dollar)

Price **\$42.37**

Change (%) ▼ **0.38 (0.89%)**

Volume 319,070

52 Week Low \$25.08

Market Cap \$1,657,613,927

Rolling EPS -3.07

PE Ratio 0

Shares Outstanding 39,122,349

Data as of August 18, 2017 4:00 p.m. ET



## Recent Press Releases & Upcoming Events

August 03, 2017

There are currently no events scheduled.

[Blueprint Medicines to Present at Upcoming Investor Conferences in August](#)

August 02, 2017

[Blueprint Medicines Reports Second Quarter 2017 Financial Results](#)

July 27, 2017

[Blueprint Medicines to Evaluate Opportunities to Advance Rare Disease Discovery Program in Fibrodysplasia Ossificans Progressiva Following Discontinuation of Collaboration with Alexion](#)

## SEC Filings

### Filing Date

### Form

August 11, 2017

4

August 09, 2017

4

August 09, 2017

8-K

August 02, 2017

10-Q

## Corporate Governance

[Jeffrey Albers](#)

Chief Executive Officer

[Marion. Dorsch, Ph.D](#)

Chief Scientific Officer

[Anthony Boral,](#)

Chief Medical

M.D-Ph.D.

Officer

Kate Haviland

Chief Business  
Officer

Christoph Lengauer,  
Ph.D.

Executive Vice  
President

Data provided by Nasdaq. Minimum 15 minutes delayed.